
Duxin Sun, PhD
College of Pharmacy
2800 Plymouth Rd
Ann Arbor, MI 48109-2800
Summary
Dr. Duxin Sun is the Charles Walgreen Jr. Professor of Pharmacy and Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Michigan. Dr. Sun serves as the Director of Pharmacokinetics (PK) Core. Dr. Sun also has joint appointment in the Chemical Biology program, the Interdisciplinary Medicinal Chemistry program, and University of Michigan’s Comprehensive Cancer Center. Dr. Sun received broad training in Pharmaceutical Sciences (PhD), Molecular Biology (visiting scientist), Pharmacology (MS) and Pharmacy (BS).
Dr. Sun’s research interests focus on drug discovery, nanomedicine and pharmacokinetics. Dr. Sun has published more than 260 papers (H-index 65), mentored 37 PhD students and 70 postdoctoral fellows/visiting scientists. Dr. Sun is a Fellow of American Association of Pharmaceutical Scientists (AAPS) and has served as chair of the PPB (Physical Pharmacy and Biopharmaceutics) in AAPS. Dr. Sun served on FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee. Dr. Sun has served on study sections for NIH and FDA.
Feature Story

When you hear the word “nanomedicine,” it might call to mind scenarios like those in the 1966 movie “Fantastic Voyage.” The film portrays a medical team shrunken down to ride a microscopic robotic ship through a man’s body to clear a blood clot in his brain. Nanomedicine has not reached that level of sophistication yet. Although scientists can generate nanomaterials smaller then several nanometers – the “nano” indicating one-billionth of a meter – today’s nanotechnology has not been able to generate functional electronic robotics tiny enough to inject safely into the bloodstream. But since the concept of nanotechnology was first introduced in the 1970s, it has made its mark in many everyday products, including electronics, fabrics, food, water and air treatment processes, cosmetics and drugs. Given these successes across different fields, many medical researchers were eager to use nanotechnology to diagnose and treat disease. While nanomedicine has seen many successes, some researchers have been disappointed by its underwhelming overall performance in cancer. What are the new ways to develop breakthroughs that allow nanomedicine to live up to its promise.
Research Interests
Drug Discovery, NanoMedicine and Pharmacokinetics
1. NanoMedicine and Drug Delivery for Cancer Immunotherapy
2. STAR (Structure-Tissue Exposure/Selectivity-Activity Relationship) Selects Better Drug Candidates and Balances Clinical Dose/Efficacy/Safety
3. Virus Spike Mimicry NanoVaccine to Activate B cell Immunity For Cancer Immunotherapy and Neutralizing Bacterial Toxin
4. Intubation and Wireless Sampling Device in Human GI Track For Microbiome Analysis and Drug Product Optimization
Selected Publications
-
Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Yudong Song, Luke Bugada, Ruiting Li, Hongxiang Hu, Luchen Zhang, Chengyi Li, Hebao Yuan, Krishani Rajanayake, Nathan Truchan, Fei Wen, Wei Gao, and Duxin Sun. Science Translational Medicine, 2022, 14 (643): online. DOI: 10.1126/scitranslmed.abl3649
-
Why 90% of clinical drug development fails and how to improve it? Duxin Sun, Wei Gao, Hongxiang Hu, Sison Zhou, Acta Pharmaceutica Sinica B, 2022, Feb, in press.
-
Structure-Tissue Exposure/Selectivity Relationship (STR) Correlates with Clinical Efficacy/Safety. Wei Gao, Hongxiang Hu, Lipeng Dai, Miao He, Hebao Yuan, Huixia Zhang, Jinhui Liao, Bo Wen, Yan Li, Maria Palmisano, Mohamed Dit Mady Traore, Simon Zhou, Duxin Sun. Acta Pharmaceutic Sinica B, 2022, Feb, in press
-
What went wrong with anticancer nanomedicine design and how to make it right. D Sun, S Zhou, W Gao. ACS nano, 2020, 14 (10), 12281-12290
-
Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. X Luan, H Yuan, Y Song, H Hu, B Wen, M He, H Zhang, Y Li, F Li, P Shu, ... Biomaterials, 2021, 120910
-
Combined p53-and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. M Gasparyan, MC Lo, H Jiang, CC Lin, D Sun. Journal of Biological Chemistry, 2020, 295 (34), 12188-12202
-
Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer additional benefit. D Sun. 2020, The AAPS journal 22, 1-6
-
Albumin nanoparticle of paclitaxel (abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer. H Yuan, H Guo, X Luan, M He, F Li, J Burnett, N Truchan, D Sun. Molecular Pharmaceutics, 2020, 17 (7), 2275-2286
-
Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. F Li, H Yuan, H Zhang, M He, J Liao, N Chen, Y Li, S Zhou, M Palmisano, ... Molecular pharmaceutics, 2019, 16 (6), 2385-2393
-
Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles. F Li, H Zhang, M He, J Liao, N Chen, Y Li, S Zhou, M Palmisano, A Yu, .... Molecular pharmaceutics, 2018, 15 (10), 4505-4516
-
Spatial and temporal analysis of the stomach and small-intestinal microbiota in fasted healthy humans. AM Seekatz, MK Schnizlein, MJ Koenigsknecht, JR Baker, WL Hasler, .... MSphere, 2019, 4 (2), e00126-19
-
Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer. CC Lin, MC Lo, R Moody, H Jiang, R Harouaka, N Stevers, S Tinsley, .... 2018, Cancer letters 438, 165-173
-
Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. YS Tan, K Sansanaphongpricha, Y Xie, CR Donnelly, X Luo, BR Heath, .... Clinical Cancer Research, 2018, 24 (17), 4242-4255
-
Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. RR Moody, MC Lo, JL Meagher, CC Lin, NO Stevers, SL Tinsley, I Jung, .... Journal of Biological Chemistry, 2018, 293 (6), 2125-2136
-
In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. MJ Koenigsknecht, JR Baker, B Wen, A Frances, H Zhang, A Yu, T Zhao, .... Molecular pharmaceutics, 2017, 14 (12), 4295-4304
-
Engineering exosomes as refined biological nanoplatforms for drug delivery. X Luan, K Sansanaphongpricha, I Myers, H Chen, H Yuan, D Sun. Acta Pharmacologica Sinica, 2017, 38 (6), 754-763
-
Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. JP Burnett, G Lim, Y Li, RB Shah, R Lim, HJ Paholak, SP McDermott, .... Cancer Letters, 2017, 394, 52-64
-
Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. A Yu, JR Baker, AF Fioritto, Y Wang, R Luo, S Li, B Wen, M Bly, Y Tsume, .... Molecular pharmaceutics, 2017, 14 (2), 345-358
-
Multibuilding Block Janus Synthesized by Seed‐Mediated Self‐Assembly for Enhanced Photothermal Effects and Colored Brownian Motion in an Optical Trap. K Sansanaphongpricha, MC DeSantis, H Chen, W Cheng, K Sun, B Wen, .... small, 2017, 13 (6), 1602569
-
Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy. HJ Paholak, NO Stevers, H Chen, JP Burnett, M He, H Korkaya, .... Biomaterials, 2016, 104, 145-157
-
Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. L Sun, J Burnett, M Gasparyan, F Xu, H Jiang, CC Lin, I Myers, H Korkaya, .... Oncotarget, 2016, 7 (32), 51408
-
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Y Li, T Zhang, H Korkaya, S Liu, HF Lee, B Newman, Y Yu, SG Clouthier, .... Clinical Cancer Research, 2010, 16 (9), 2580-2590
-
Characterization of celastrol to inhibit hsp90 and cdc37 interaction. T Zhang, Y Li, Y Yu, P Zou, Y Jiang, D Sun. Journal of Biological Chemistry, 2009, 284 (51), 35381-35389
-
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. T Zhang, A Hamza, X Cao, B Wang, S Yu, CG Zhan, D Sun. Molecular cancer therapeutics, 2008, 7 (1), 162-170
-
Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. X Cao, M Bloomston, T Zhang, WL Frankel, G Jia, B Wang, NC Hall, .... Clinical Cancer Research, 2008, 14 (6), 1831-1839
-
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. X Cao, ST Gibbs, L Fang, HA Miller, CP Landowski, HC Shin, .... Pharmaceutical research 2006, 23 (8), 1675-1686
-
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. D Sun, H Lennernas, LS Welage, JL Barnett, CP Landowski, D Foster, .... Pharmaceutical research, 2002, 19 (10), 1400-1416
-